smoking and cardiovascular
disease 2: 105
smoking and pulmonary disease
2: 230
TIA 2:111
stupor 1:284–285
subcutaneous injection 1:367;
4: 385
subcutaneous layer 1:128, 195
sublingual (drug) 4:169, 325
substance abuse 3:367, 369, 378,
381, 385; 4:311–354, 312 t, 354
substance abuse prevention
4:47–48
substance abuse treatment 4:315,
325, 344, 350, 351–352
substantia nigra 1:127, 178, 232
sudden cardiac death 2:108
CAD 2: 43
cardiac arrest 4: 372
cardiomyopathy 2: 32
congenital heart disease 2: 39
heredity and heart disease 2: 63
LQTS 2: 74
sarcoidosis 2: 293
stimulants 4: 351
torsade de pointes 2: 111
Wolff-Parkinson-White
syndrome 2: 117
sudden infant death syndrome
(SIDS) 2:121, 184; 4:48
suicidal ideation and suicide 3:371,
383 , 385–386
sunburn 1:200–201
burns 4: 364
dong quai 4: 66
Fitzpatrick skin type 1: 158
keratitis 1: 99
photosensitivity 1:183–184
skin cancer 1:196, 198
sun protection 1:201–202
vitiligo 1: 207
sunlight 1:128, 175
sun protection 1:134–136, 172,
196, 198, 201–202, 315
Sun’s Soup 4:99–100
superior vena cava 2:4, 115
support groups 1:223; 4:254, 292 ,
305 , 314 , 320
suppressor T-cells 2:253, 254, 296
suprachiasmatic nucleus (SCN)
3:145, 151, 155
Surgeon General’s Report. See
Smoking and Health: Report of the
Advisory Committee to the Surgeon
General of the Public Health Service
Surgeon General’s Report (1964).
See Smoking and Health: Report of
the Advisory Committee to the
Surgeon General of the Public Health
Service
surgery 4:257–281. See also specific
forms of surgery
surgery benefit and risk assessment
4:277–279, 277 t, 278 t. See also
specific forms of surgery, e.g.:open
heart surgery
surgery for cancer 2:370, 386, 391,
393–394
swallowing disorders 1:25, 32,
55–56,60; 2:222, 234; 3:9, 42;
4:6, 183, 198, 373
sweat glands 1:128, 164–165, 195,
202
sweating 4:184, 374, 375
swimmer’s ear (otitis externa) 1:21,
40
sympathetic nervous system 1:216,
371
symptom assessment and care
triage 4:359–360
synaptic vesicles 3:125, 152
syncope 2:108–109
blood pressure 2: 24
hypotension 2:67–68
palpitations 2: 93
PAT 2: 94
sick sinus syndrome 2: 104
TIA 2: 111
Wolff-Parkinson-White
syndrome 2: 116
syndactyly 1:357
syndrome X. Seeinsulin resistance
synovial capsule 1:307, 328
synovial membrane 1:312, 357
synovitis 1:357
syphilis 1:186; 2: 130 , 355–356;
4: 46
systemic lupus erythematosus (SLE)
2:295–296, 296 t;3:207; 4: 148
antiphospholipid antibodies
2: 249
complement cascade 2: 256
DLE 1:152–153
immunoglobulin 2: 275
immunosuppressive medications
2: 276
immunosuppressive therapy
2: 276
sialadenitis 1: 50
Sjögren’s syndrome 2: 294
thymus 2:120–121, 172systole 2:34, 41, 54, 70, 217
systolic measure 2:24, 66T
tachycardia 2:17, 55, 223; 4:367,
374
tachypnea 2:181, 191, 199, 223,
232; 4:330, 367
tai chi 4: 88 , 101,106, 224
talipes equinovarus 1:358
tamoxifen 3:252, 276
tamponade, cardiac 2: 95 , 110
tardive dyskinesia 1:252; 4: 148
taste 1:4, 8
tattoos 1:203
taxanes 2:376, 376t
Tay-Sachs disease 4: 128 , 142–143
TBI. Seetraumatic brain injury
TCAs. Seetricyclic antidepressants
T-cell lymphocyte 1:339; 2:296;
3:100, 160, 205
aging and changes in
blood/lymph 2: 123
aging and immune response
2: 239
antibody-mediated immunity
2: 246
antigen 2: 246
BALT 2: 251
berylliosis 2: 192
cell-mediated immunity 2: 253
clusters of differentiation 2: 254
graft vs. host disease 2:264, 265
HIV/AIDS 2:334, 335
hypersensitivity reaction 2:268,
269
immune system 2:235–237
immunotherapy 2: 276
interferons 2: 278
lymph node 2: 151
lymphocyte 2: 151
lymphokines 2: 281
lymphoma 2: 152
MALT 2: 284
MHC 2: 282
NALT 2: 287
thymectomy 2: 172
thymus 2:120–121, 172
tea 4:145, 326. See alsogreen tea
tear ducts. Seelacrimal ducts
tear glands (Sjögren’s syndrome)
2:294–295
tears 1:65, 85–87
teeth 1:358
addiction 4: 314
dental caries 1:20Index 507